Novo Nordisk/DKr NOVO B
1D1W1MYTD1Y5YMAX
Capital at risk
About Novo Nordisk
Novo Nordisk A/S is a global healthcare company specializing in diabetes care and hormone replacement therapies. Headquartered in Bagsværd, Denmark, the company is renowned for its insulin and GLP-1 receptor agonists for treating diabetes, as well as products for obesity care and growth hormone therapy. Established in 1923, Novo Nordisk has grown its presence worldwide, operating in numerous countries with a substantial workforce. The company leverages its scientific research capabilities to maintain a strong position in the biopharmaceutical industry, focusing heavily on innovation in chronic disease management. Its integrated supply and production facilities support its strategic emphasis on quality control and sustainable production practices.
- Ticker
- DKr NOVO B
- Sector
- Health
- Primary listing
- CSE
- Employees
- 66,700
- Headquarters
- Bagsvaerd, Denmark
- Website
- www.novonordisk.com
Novo Nordisk Metrics
BasicAdvanced
kr 1.2T
10.56
kr 26.20
0.35
kr 11.70
4.23%
Price and volume
Market cap
kr 1.2T
Beta
0.35
52-week high
kr 409.95
52-week low
kr 224.25
Average daily volume
4.3M
Dividend rate
kr 11.70
Financial strength
Current ratio
0.873
Quick ratio
0.642
Long term debt to equity
55.041
Total debt to equity
63.327
Dividend payout ratio (TTM)
44.64%
Interest coverage (TTM)
1,566.84%
Profitability
EBITDA (TTM)
173,677
Gross margin (TTM)
81.99%
Net profit margin (TTM)
35.35%
Operating margin (TTM)
48.99%
Effective tax rate (TTM)
21.72%
Revenue per employee (TTM)
kr 4,940,000
Management effectiveness
Return on assets (TTM)
18.73%
Return on equity (TTM)
59.82%
Valuation
Price to earnings (TTM)
10.56
Price to revenue (TTM)
3.729
Price to book
5.53
Price to tangible book (TTM)
12.34
Price to free cash flow (TTM)
25.707
Free cash flow yield (TTM)
3.89%
Free cash flow per share (TTM)
10.762
Dividend yield (TTM)
4.23%
Growth
Revenue change (TTM)
5.61%
Earnings per share change (TTM)
4.98%
3-year revenue growth (CAGR)
17.84%
10-year revenue growth (CAGR)
11.56%
3-year earnings per share growth (CAGR)
20.74%
10-year earnings per share growth (CAGR)
14.01%
3-year dividend per share growth (CAGR)
18.26%
10-year dividend per share growth (CAGR)
9.55%
Bulls say / Bears say
European Commission approved the Wegovy pill as the first oral GLP-1 therapy for obesity management across the EU on July 15, 2026, based on robust OASIS 4 data and further expanding Novo’s obesity portfolio in key markets. (Reuters)
On March 9, 2026, Novo Nordisk struck a deal to distribute its GLP-1 injectables Wegovy and Ozempic via Hims & Hers Health’s telehealth platform, resolving a legal dispute and broadening U.S. distribution channels for its top-selling drugs. (Reuters)
Novo’s Q2 2026 adjusted operating profit of DKK 33.4 billion beat analysts’ forecasts, and the company raised its full-year 2026 profit and sales guidance, driven by strong GLP-1 momentum in the U.S. and continued international launches. (Reuters)
CEO Mike Doustdar warned on February 4, 2026, of “unprecedented” U.S. price pressures that would drive 2026 sales and profit declines, triggering a roughly 17% share drop and casting doubt on near-term growth. (Reuters)
Eli Lilly’s Q2 2026 sales of its injectable GLP-1 drugs Zepbound and Mounjaro surged past estimates, widening the market share gap with Novo and underscoring intensifying competitive pressure. (Reuters)
Novo’s August 4, 2026 Q2 update disappointed investors with a narrow sales miss for its newly launched Wegovy pill and a trial setback for next-generation obesity candidate CagriSema, highlighting execution and pipeline risks. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Upcoming events
No upcoming events
Funds containing Novo Nordisk
AllEURGBPUSD
Fund name | Fund size | DKr NOVO B weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 8.71% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 8.71% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 7.78% |
iShares STOXX Europe 50€EXW3 | €141M | 3.09% |
VanEck Morningstar Developed Markets Dividend Leaders€TDIV | €754M | 2.37% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.